ClinicalTrials.gg
RecruitingNCT07016269Updated Jul 29, 2026

A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia

A Phase 4 interventional study of CnU capsule 500 mg(250mg 2 capsule) and CnU placebo capsule 500 mg(250mg 2 capsule) in Biliary Dyspepsia, sponsored by Myungmoon Pharma. Co. Ltd.. Recruiting at 8 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Myungmoon Pharma. Co. Ltd. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Dyspepsia with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Dyspepsia · Korea, Republic of.

Planned enrollment
4th of 26
358 · median 100
Started
2025
with 1 other
Phase 4
8 of 28
2 open now
Registered
26th of 28
by date

Among the 28 studies in Dyspepsia with a site in Korea, Republic of, this one is the 4th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 in phase 4, and was the 26th registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

3 of the 28 studies in Dyspepsia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Dyspepsia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 500 mg administration in patients with biliary dyspepsia

03

Conditions studied

  • Biliary Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[Inclusion Criteria]

  1. Individuals who have voluntarily agreed to participate in this clinical trial
  2. Adults aged 19 years and older
  3. Individuals with pain localized to the epigastrium and/or right upper quadrant, as defined by the ROME IV diagnostic criteria

    • Rome IV criteria(Functional gallbladder and sphincter of Oddi disorders Diagnostic criteria) 1) Builds up to a steady level and lasts 30 minutes or longer 2) Occurring at different intervals (not daily) 3) Severe enough to interrupt daily activities or lead to an emergency department visit 4) Not significantly (\<20%) related to bowel movements 5) Not significantly (\<20%) relieved by postural change or acid suppression
    • Supportive criteria:

The pain may be associated with:

1) Nausea and vomiting 2) Radiation to the back and/or right infrasubscapular region 3) Waking from sleep

4. Individuals without any organic lesions on abdominal ultrasonography performed during screening that could explain biliary colic symptoms due to gallstones

[Exclusion Criteria]

1. Medical History

  1. Patients with frequent biliary colic or biliary tract infections (e.g., severe pancreatic changes such as ileal resection, surgery, or partial ileitis, which may alter the composition of enterohepatic bile acid circulation).
  2. Patients with obstructive jaundice.
  3. Patients with liver disease.
  4. Patients with severe renal disease.
  5. Patients with severe biliary obstruction (due to the potential choleretic effect, symptoms may worsen).
  6. Patients with underlying conditions that may worsen biliary obstruction (e.g., cholangiocarcinoma, cholangitis, biliary cysts).
  7. Patients with acute cholecystitis.
  8. Patients with a clear etiology of dyspepsia (e.g., those with endoscopically or clinically confirmed GI abnormalities such as gastric ulcer, gastroparesis; regular NSAID users; or those with prominent heartburn).
  9. Patients with peptic ulcer disease (due to the potential for mucosal irritation and symptom aggravation).
  10. Patients with inflammatory bowel diseases such as Crohn's disease.
  11. Patients with cholestasis.
  12. Patients with abnormal gallbladder contractility.
  13. Patients with a history of within 5 years prior to screening.
  14. Patients with a history of gastrointestinal surgery.
  15. Patients known to be hypersensitive to any components or of the product.
  16. Patients with disorders of the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems, or with a history or presence of psychiatric illness that may significantly affect participation in the study.
  17. Individuals with a history of drug or alcohol abuse.

2. Abnormal Laboratory Findings at Screening

  1. (BMI) ≥ 35 kg/m².
  2. or AST > 2.0 × upper normal limit (UNL).
  3. Total > 2.0 × UNL.
  4. Estimated (eGFR) \< 60 mL/min/1.73 m² (based on the CKD-EPI equation).
  5. Positive serologic test results for any of the following:

    - surface antigen (HBsAg)

    • antibody (HCV Ab)
    • antibody (HIV Ab)
    • Syphilis reagin test

      3. Prohibited Concomitant Medications and Therapies

Subjects taking the following medications must undergo the specified before enrollment:

  1. Within 1 week prior to screening: Drugs that stimulate bile secretion (e.g., estrogens, hormonal , certain lipid-lowering agents) Drugs that reduce blood cholesterol (e.g., clofibrate)
  2. Within 2 weeks prior to screening: Cholestyramine, colestipol, activated charcoal, or antacids containing magnesium or aluminum hydroxide
  3. Within 4 weeks prior to screening: Oral gallstone-dissolving agents such as chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), HMG-CoA reductase inhibitors, or terpene-based drugs
  4. Within 4 weeks prior to screening: Bile acid therapies

    The following medication is strictly prohibited, regardless of washout period:

    • Alpha-methyldopa

      4. Pregnant or lactating women will be excluded from the study.

      5. Contraception

    Subjects or their partners who are not using medically acceptable methods of contraception throughout the study period will be excluded. Acceptable methods include:

1) Proven intrauterine devices (IUD) or intrauterine systems (IUS) 2) Dual barrier methods (e.g., male condom with diaphragm or cervical cap, used with a spermicide) 3) Permanent sterilization (e.g., vasectomy, tubal ligation, salpingectomy, or hysterectomy)

6. Other Individuals deemed by the investigator to be unsuitable for participation in this clinical trial for any reason.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
358 participants (estimated)

Study arms

  • Experimental
    CnU capsule 500 mg(250mg 2 capsule)

    Drug: CnU capsule 500 mg(250mg 2 capsule)

  • Placebo comparator
    CnU placebo capsule 500 mg(250mg 2 capsule)

    Drug: CnU placebo capsule 500 mg(250mg 2 capsule)

Interventions

  • DrugCnU capsule 500 mg(250mg 2 capsule)

    According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

  • DrugCnU placebo capsule 500 mg(250mg 2 capsule)

    According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.

06

What researchers measure

Primary outcomes

  1. Symptom improvement rate at Week 24 using the Global Overall Symptom Scale (GOS) in patients with biliary dyspepsia

    * Description: The Global Overall Symptom Scale assesses the overall severity of upper abdominal symptoms such as pain or discomfort, bloating, excessive belching, and nausea. Symptoms are rated on a 7-point Likert scale, where 1 = no symptoms and 7 = very severe symptoms. * Outcome Definition: Improvement is defined as a decrease of 2 or more points compared to baseline. * Unit of Measure: Percentage of participants with ≥2-point reduction

    Time frame: Baseline and Week 24

Secondary outcomes

  1. 1. Symptom improvement rate using the GOS in patients with biliary dyspepsia 2. Change in dyspepsia symptom scores using the NDI-K 3. Change in quality of life scores using the NDI-K

    1. Symptom improvement rate at Weeks 4 and 12 using the GOS in patients with biliary dyspepsia * Time Frame: Baseline, Week 4, and Week 12 * Description: The GOS evaluates upper abdominal symptoms using a 7-point Likert scale, where 1 = no symptoms and 7 = very severe symptoms. * Outcome Definition: Improvement is defined as a decrease of 2 or more points compared to baseline. * Unit of Measure: Percentage of participants with ≥2-point reduction 2. Change in dyspepsia symptom scores from baseline using the NDI-K * Time Frame: Baseline, Week 4, Week 12, and Week 24 * Outcome Definition: Change in total and subscale scores from baseline. * Unit of Measure: Mean change in score 3. Change in quality of life scores from baseline using the NDI-K QoL subscale * Time Frame: Baseline, Week 4, Week 12, and Week 24 * Outcome Definition: Change in QoL subscale scores from baseline * Unit of Measure: Mean change in score

    Time frame: Baseline, Week 4, Week 12, and Week 24

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 26 months after the start.

Of 31 phase 4 interventional studies under Dyspepsia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
Jun 11, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Nov 10, 2027
CompletionEst.
Jun 13, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016269
Lead sponsor
Myungmoon Pharma. Co. Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Aug 29, 2025
Primary completion
Nov 10, 2027 (estimated)
Completion
Jun 13, 2028 (estimated)
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion